Completed enrollment in Phase 2 Clinical Trial; data readout expected during calendar 3Q 2023 120% quarter-over-quarter revenue growth in the commercial BayMedica subsidiary Published a peer-reviewed study showing the anti-inflammatory… Read More
Three poster presentations at ASGCT 2023 will highlight the development of Aspect’s bioprinted liver tissue platform VANCOUVER, BC — Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue… Read More
Phase 1 clinical trial dosing completed Phase 1b/2a clinical trial of NVG-291 in individuals with chronic and subacute spinal cord injuries expected to commence in Q3 2023 Cash and investments of $18.0 million as… Read More
OTTAWA, ON | Public Health Agency of Canada Antimicrobials, such as antibiotics, save lives every day. Without effective antimicrobials, common infections could become untreatable and even life-threatening for humans and… Read More
TORONTO, ON — Takeda Canada Inc. (“Takeda”) announces results from the EVOLVE Expansion study, which evaluated the safety and efficacy of vedolizumab (ENTYVIO®), a gut-selective α4β7-integrin inhibitor and ustekinumab (UST), an… Read More
